Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 2,386 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progressive Clear all
Terminated Phase 2 Interventional Results available

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

NCT01095094
View directory record Official record
Conditions
Brain Tumor, Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Brain Stem Glioma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Mixed Glioma
Interventions
ritonavir, lopinavir
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 24, 2026, 2:54 PM EDT
Recruiting Not applicable Interventional

Remotely-supervised Neuromodulation in PPA

NCT07260253
View directory record Official record
Conditions
Primary Progressive Aphasia(PPA), Progressive Aphasia, Progressive Aphasia in Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Logopenic Variant Primary Progressive Aphasia, Logopenic Variant of Primary Progressive Aphasia (LPA)
Interventions
Lexical Retrieval Cascade Treatment, Remotely Supervised Transcranial Direct Current Stimulation- Active, Remotely Supervised Transcranial Direct Current Stimulation - Sham
Behavioral · Device
Lead sponsor
Maya Henry
Other
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
San Francisco, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 24, 2026, 2:54 PM EDT
Terminated Phase 2 Interventional Results available

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT01812005
View directory record Official record
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Interventions
alisertib, rituximab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 24, 2026, 2:54 PM EDT
Not listed Not applicable Interventional

Treadmill Oscillation Walking to Improve Weight Transfer During Gait Following Stroke

NCT05541705
View directory record Official record
Conditions
Treadmill Walking
Interventions
Treadmill Oscillation Walking
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 24, 2026, 2:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

NCT00050986
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Temozolomide, R115777
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 24, 2026, 2:54 PM EDT
Recruiting No phase listed Observational

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

NCT05361694
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 24, 2026, 2:54 PM EDT
Completed Phase 2 Interventional

Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma

NCT01777594
View directory record Official record
Conditions
Advanced Adult Hepatocellular Carcinoma
Interventions
G-202
Drug
Lead sponsor
GenSpera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Dallas, Texas • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Oct 24, 2026, 2:54 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Hyperopia Correction Using the NTK Optimal Keratoplasty (Opti-K) System

NCT01028937
View directory record Official record
Conditions
Hyperopia
Interventions
Optimal Keratoplasty
Device
Lead sponsor
NTK Enterprises, Inc.
Industry
Eligibility
40 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 24, 2026, 2:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

NCT03123783
View directory record Official record
Conditions
Cancer, Non Small Cell Lung Cancer Metastatic, Metastatic Melanoma, Neoplasm of Lung, Melanoma
Interventions
APX005M, Nivolumab
Drug
Lead sponsor
Apexigen America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Tucson, Arizona • Duarte, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 24, 2026, 2:54 PM EDT
Completed Phase 1 Interventional

Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis

NCT03493841
View directory record Official record
Conditions
Multiple Sclerosis, Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Alpha Lipoic Acid
Drug
Lead sponsor
Rebecca Spain
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 24, 2026, 2:54 PM EDT
Terminated Phase 2 Interventional Results available

Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer

NCT00132002
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
vorinostat, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Oct 24, 2026, 2:54 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas

NCT07003542
View directory record Official record
Conditions
Glioblastoma, Brain Tumor
Interventions
Sitagliptin
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 24, 2026, 2:54 PM EDT
Withdrawn Phase 2 Interventional

Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy

NCT05204160
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Pembrolizumab
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 24, 2026, 2:54 PM EDT
Recruiting Phase 2 Interventional

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

NCT01356290
View directory record Official record
Conditions
Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor Recurrent
Interventions
Bevacizumab, Thalidomide, Celecoxib, Fenofibric acid, Etoposide, Cyclophosphamide, Cytarabine, Temozolomide (TMZ), Irinotecan
Drug
Lead sponsor
Medical University of Vienna
Other
Eligibility
Up to 19 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 2:54 PM EDT
Completed Phase 3 Interventional

Correction of Myopia Evaluation Trial (COMET)

NCT00000113
View directory record Official record
Conditions
Myopia
Interventions
Progressive Addition Lenses, single vision lenses
Other
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 12 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2013
U.S. locations
4
States / cities
Birmingham, Alabama • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 24, 2026, 2:54 PM EDT
Not yet recruiting Not applicable Interventional

Self-Compassion, Health, and Empowerment

NCT07733531
View directory record Official record
Conditions
Intimate Partner Violence (IPV), Depression and/or Anxiety Symptoms, PTSD - Post Traumatic Stress Disorder
Interventions
The Self-Compassion, Health, and Empowerment (SHE) Intervention, Health and Nutrition Program
Behavioral
Lead sponsor
Yang Li
Other
Eligibility
18 Years and older · Female only
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 24, 2026, 2:54 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Diagnostic and Prognostic Biomarkers in Parkinson Disease

NCT00653783
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
The Parkinson Study Group
Network
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2008 · Synced Oct 24, 2026, 2:54 PM EDT
Recruiting Not applicable Interventional

Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)

NCT07176273
View directory record Official record
Conditions
Posttraumatic Stress Disorder, PTSD
Interventions
Modular Cognitive Processing Therapy, Modular Prolonged Exposure Therapy, Step Down Treatment, Digital Interventions, Cognitive Processing Therapy (CPT), Prolonged Exposure (PE)
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Augusta, Georgia • Ann Arbor, Michigan • Battle Creek, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 24, 2026, 2:54 PM EDT
Recruiting Phase 2 Interventional

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

NCT06955169
View directory record Official record
Conditions
Intracranial Meningioma
Interventions
[177Lu]Lu-DOTATATE, Standard of Care treatments
Drug · Other
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 2:54 PM EDT
Completed Phase 1 Interventional

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

NCT00979862
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions
Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 24, 2026, 2:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Concussion Therapy Intervention Training in Healthy and Concussed Participants

NCT02872480
View directory record Official record
Conditions
Cerebral Concussion
Interventions
ACTIVE Training
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 24, 2026, 2:54 PM EDT
Active, not recruiting No phase listed Observational

Prospective Decision Impact Trial of KidneyIntelX

NCT04960514
View directory record Official record
Conditions
Diabetic Kidney Disease, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease, Stage 3 (Moderate)
Interventions
KidneyIntelX
Diagnostic Test
Lead sponsor
Renalytix AI, Inc.
Industry
Eligibility
23 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 24, 2026, 2:54 PM EDT
Not listed Phase 1 Interventional

Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma

NCT00591058
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma, Oligodendroglioma
Interventions
TM-601
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2009 · Synced Oct 24, 2026, 2:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)

NCT00950248
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Idebenone, placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 24, 2026, 2:54 PM EDT